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Abstract
Background: Autotaxin (ATX) is an extracellular lysophospholipase D that generates lysophosphatidic acid (LPA) from 
lysophosphatidylcholine (LPC). Both ATX and LPA have been shown to be involved in many cancers. However, the 
functional role of ATX and the regulation of ATX expression in human hepatocellular carcinoma (HCC) remain elusive.
Results: In this study, ATX expression was evaluated in tissues from 38 human HCC and 10 normal control subjects. ATX 
was detected mainly in tumor cells within tissue sections and its over-expression in HCC was specifically correlated 
with inflammation and liver cirrhosis. In addition, ATX expression was examined in normal human hepatocytes and 
liver cancer cell lines. Hepatoma Hep3B and Huh7 cells displayed stronger ATX expression than hepatoblastoma 
HepG2 cells and normal hepatocytes did. Proinflammtory cytokine tumor necrosis factor alpha (TNF-α) promoted ATX 
expression and secretion selectively in Hep3B and Huh7 cells, which led to a corresponding increase in 
lysophospholipase-D activity. Moreover, we explored the mechanism governing the expression of ATX in hepatoma 
cells and established a critical role of nuclear factor-kappa B (NF-κB) in basal and TNF-α induced ATX expression. Further 
study showed that secreted enzymatically active ATX stimulated Hep3B cell invasion.
Conclusions: This report highlights for the first time the clinical and biological evidence for the involvement of ATX in 
human HCC. Our observation that links the TNF-α/NF-κB axis and the ATX-LPA signaling pathway suggests that ATX is 
likely playing an important role in inflammation related liver tumorigenesis.
Background
Hepatocellular carcinoma/cancer (HCC) is one of the
most common malignant tumors worldwide [1]. It most
often develops in the background of underlying liver dis-
ease, such as hepatitis. Historically a challenge for Asian
countries, the increasing incidence of hepatitis C has
made HCC a major health problem within the United
States in recent years [2]. Early stage HCC is potentially
curable with liver transplant or resection. However, most
patients present with more advanced disease and for
these patients' treatment options are limited. Inroads into
effective therapies have been thwarted by a gap in our
understanding of the molecular mechanisms involved in
cancer development and progression within its complex
microenvironment. Therefore, studies elucidating the
mechanism and signaling pathways involved in HCC
development and progression are imperative.
Previous microarray analysis from our laboratory iden-
tified autotaxin (ATX) as one a gene with enhanced
mRNA expression in human hepatitis associated HCC
[3]. Reports from other labs showed that serum ATX
activity and plasma lysophosphatidic acid (LPA) level are
increased in various liver injuries in rats in relation to
their severity [4]. ATX was initially characterized as an
autocrine motility factor from A2058 melanoma cell con-
ditioned medium [5]. It has been subsequently shown
that ATX acts as an important mediator of tumorigenesis
by stimulating angiogenesis, as well as survival, growth,
migration, and invasion of tumor cells [6-8]. In particular,
recent studies using ATX knockout mice suggest that
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Page 2 of 14ATX contributes to tumor progression by stabilizing
blood vessels in the vicinity of tumors [9,10]. Although
ATX has been showed to affect adhesion through integ-
rin-dependent focal adhesion assembly [11,12], the main
impact of ATX on cancer biology is mostly due to its
intrinsic lysophospholipase D (lyso-PLD) activity.
Through the conversion of lysophosphatidylcholine
(LPC) into LPA and to a less degree, sphingosylphospho-
rylcholine (SPC) into sphingosine-1-phosphate (S1P)
[13,14], ATX regulates cell activation by changing signal-
ing induced by LPC versus LPA.
LPA is an important lipid mediator that elicits a broad
spectrum of biological effects by activating G protein-
coupled receptors (GPCRs). The biological functions of
LPA included, but not limited to cell proliferation, migra-
tion, platelet aggregation, smooth muscle contraction,
and cytoskeletal reorganization. In the context of cancer,
LPA could induce stress fiber formation, membrane ruf-
fling, and lamellipodia formation [15-17]. The aberrant
ATX expression may lead to altered LPC/LPA balance
and their receptor-mediated functions, resulting in
enhanced tumor progression. Hence, the molecular
events that lead to the aberrant ATX expression and the
subsequent abnormal LPA production are significant for
understanding the mechanisms involved in cancer pro-
gression. In this study, we examined the expression of
ATX antigen in HCC tissue using immunohistochemis-
try. The regulatory mechanism of ATX by the key inflam-
matory component TNF-α/NF-κB axis was studied in
human hepatoma cell lines. We also demonstrated that
ATX is involved in the invasive potential of HCC cells.
Results
ATX antigen expression in human HCC
We have previously examined ATX mRNA expression in
human HCC tissues [3]. Here we investigated the ATX
protein expression by immunohistochemical approach in
tissues form 38 HCC cases and 10 normal controls. The
overall positive staining of ATX in normal samples was
20%, with a small portion of stromal cells showed weak
ATX immunoreactivity, but not normal hepatocytes (Fig-
ure 1A and 1B). In contrast, the overall positive rate of
ATX protein expression in HCC was 89% (34 of 38). ATX
expression was varied from weak to strong, and the
majority of immunoreactivity was heterogeneously dis-
tributed in the cytoplasm of tumor cells (Figure 1C-J).
Thus, ATX protein expression was significantly increased
in HCC tissues when compared with normal liver speci-
mens.
Correlation between ATX overexpression and 
clinicopathological parameters in human HCC
Table 1 showed the correlation of ATX levels with clini-
copathologic features. Among the 38 HCC samples, 21
(55%) cases were scored 3+, 5 (13%) cases 2+, 8 (21%)
cases 1+, and 4 (10.5%) cases 0. Fisher exact test was
applied to assess the correlations between ATX expres-
sion and clinic pathologic variables of HCC. High expres-
sion of ATX was more frequent in HCC with risk factors
such as hepatitis compared to the HCCs which were
developed from normal liver background with neither
inflammatory lesions nor identified risk factors (Normal-
HCC) (P = 0.0053). A statistical difference in expression
of the ATX protein between HCC associated with an
inflammatory background and those without inflamma-
tory changes in the adjacent liver was also evident (P =
0.0003). In addition, HCC without cirrhosis displayed
lower level of ATX expression than those with cirrhosis
(P = 0.00031). These data have not only confirmed our
previous observation at the protein level, but also
revealed its association with inflammation, which sup-
port the potential role of ATX in the pathogenesis of
human HCC.
Differential expression of ATX in human liver cell lines
To gain a better insight into the expression and function
of ATX in HCC, we examined the expression of ATX in
three human liver cancer cell lines (Hep3B, Huh7 and
HepG2), a human normal embryonic liver cell line CL-48,
and human normal primary hepatocytes. As shown in
Figure 2A, quantitative real time RT-PCR (qRT-PCR)
revealed that ATX expression in Hep3B and Huh7 cells
was 42- and 14-folds higher than that of HepG2 cells,
respectively, while the expression of ATX mRNA in CL-
48 was negligible when compared with that of Hep3B
cells (AvgCt ~37.5 vs. AvgCt ~21.0). Human normal pri-
mary hepatocytes also displayed very low level of ATX
mRNA (AvgCt ~32.4). ATX mRNA expression levels in
these cells were well-correlated to its protein expression
levels determined by immunoblot analysis. ATX protein
expressed at higher levels in Hep3B and Huh7 cells than
in HepG2 cells. The ATX protein levels in CL-48 cells and
normal primary hepatocytes were even lower than that in
HepG2 cells (Figure 2B, the top panel). Since ATX protein
can be secreted from cells, and the soluble ATX has been
considered to be mainly responsible for extracellular LPA
production (12), we measured secreted ATX levels in cul-
tural media from these cells. Only Hep3B and Huh7 pro-
duced measurable amounts of secreted ATX in their
conditioned media (Figure 2B, the bottom panel). These
results are consistent with our immunohistologic studies
shown in Figure 1, suggesting aberrant ATX expression
and regulation in human HCC.
ATX expression and secretion were selectively promoted by 
proinflammatory cytokine TNF-α
The expression of ATX is regulated by growth factors and
cytokines. For example, FGF and EGF have been shown
to induce ATX expression, whereas certain cytokines
such as interleukin-1 (IL-1), IL-4 and interferon-gamma
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Figure 1 Representative microphotographs of immunohistochemical analysis of ATX antigen expression in human normal liver and HCC 
tissue. A, B, normal control liver (NL). C, D, HCCs developed from normal liver background with neither inflammatory lesion nor well-established risk 
factors, and were classified as normal-HCC (N-HCC). E, F, Hepatitis B-related HCC (HBV-HCC). G, H, hepatitis C-related HCC (HCV-HCC). I, J, nonalcoholic 
steatohepatitis (NASH) related-HCC (NASH-HCC). No detectable ATX antigen expression was observed in hepatocytes of normal liver although a small 
portion of stromal cells showed weak ATX immunoreactivity (A and B, blue arrow). Intense and widespread ATX immunoreactivity was observed in 
the cytoplasm of tumor cells in HBV-, HCV- or NASH-associated HCC (E-J, red arrow). Weak ATX immunoreactivity was observed in the tumor cells of 
N-HCC (C and D, blue arrow). A, C, E, G, and I, original magnification, × 200; B, D, F, H and J, original magnification, × 400. Images were captured with 
a Leica DM5000 B system (Leica Microsystems).
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Table 1: Correlations between ATX expression and clinicopathologic variables of 38 patients with HCC.
Clinicopathologic variables ATX expression P
Subtotal 0 1+ 2+ 3+
Age P = 1
< = 50 6 1 1 1 3
>50 29 3 4 6 16
Gender P = 0.836
Male 32 3 7 5 17
Female 6 1 1 0 4
Etiology P = 0.0053
HBV 7 0 0 0 7
HCV 11 0 2 1 8
NASH 10 0 3 2 5
Normal-HCC 10 4 3 2 1
Inflammation P = 
0.00031
Without 10 4 3 2 1
With 28 0 5 3 20
Tumor grade P = 0.932
I 22 2 4 3 13
II 9 2 3 1 6
III 4 0 1 1 2
Lymphovascular invasion P = 0.414
Absence 26 2 5 4 15
Presence 9 2 3 1 3
Tumor nodule no. P = 0.927
Multiple(> = 2) 8 1 1 1 5
Solitary 27 3 7 4 13
Serum AFP (ug/L) P = 0.3585
< = 20 22 1 6 3 12
>20 7 1 0 1 5
Liver cirrhosis P = 0.0003
Absence 10 4 3 2 1
Presence 28 0 5 3 20
Note: The expression of ATX was determined in 38 cases of HCC by immunohistochemical studies as described in Materials and Methods. The 
correlations between ATX expression and clinicopathologic variables of HCCs were evaluated by the Fisher exact test. Statistically significant 
values are in bold. Some clinicopathologic factors only included 35 or less cases information as several cases missed part of the 
clinicopathologic information.
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tured fibroblast-like synoviocytes (SFC) [18]. Inflamma-
tory cytokines are known to be associated with the
inflammation related liver diseases [19]. Here we exam-
ined the effect of a prototype inflammatory cytokine,
TNF-α on the expression of ATX in human liver cell
lines. Assessed by QRT-PCR assays, TNF-α engagement
increased ATX mRNA levels more than 3-fold and 1.7-
fold in Hep3B cells and Huh7 cells, respectively. In con-
trast, TNF-α did not affect ATX expression in either
HepG2 or CL-48 cells (Figure 3A). The stimulatory effect
of TNF-α on cellular and secreted ATX protein expres-
sion was further demonstrated by immunoblot analyses
(Figure 3B).
Up-regulation of ATX induced by TNF-α was associated 
with increased Lyso-PLD activity by conversion of LPC into 
LPA
Being an enzyme with lyso-PLD activity, ATX plays a
critical role in LPA production [13]. In order to explore
whether TNF-α-induced ATX led to a corresponding
increase in ATX/lyso-PLD activity, we collected condi-
tioned media from Hep3B and Huh7 cells that were
treated with TNF-α or vehicle (0.1%BSA/PBS). ATX/lyso-
PLD activity in conditioned media was measured with
fluorescent LPC analogue FS-3 as substrate [20]. The
basal level of lyso-PLD activity secreted by Hep3B cells
was higher than that from Huh7 cells. After TNF-α stim-
ulation, both Hep3B and Huh7 exhibited a ~1.5-fold
increase of secreted lyso-PLD activity (P < 0.01, Figure
4A), indicating that TNF-α was able to increase lyso-PLD
activity in cell culture media by inducing ATX expression.
We next checked the LPA production by incubating the
conditioned media with 15 μM LPC (18:1), a lyso-PLD
substrate, followed by liquid chromatography/Mass spec-
trometry (LC-MS) analysis. The media from either vehi-
cle- or TNF-α-treated Hep3B cells contained low levels of
LPA (18:1) (2.52 ± 1.39 and 2.93 ± 0.53 nmol/L, respec-
tively). After supply of ATX substrate (LPC), relatively
high levels of LPA (167.6 ± 11.8 nmol/L 18:1-LPA) were
detected in the conditioned medium of Hep3B cells.
TNF-α treatment further elevated LPA levels by more
than 1.5-fold (257.7 ± 24.79 nmol/L 18:1-LPA, P < 0.05).
In parallel, more LPC was hydrolyzed in TNF-α treated
group than control group (data not shown). A similar
effect was observed in Huh7 cells, where TNF-α treat-
ment induced an approximately 1.8-fold increase of LPA
generation (73.15 ± 18.1 nmol/L 18:1-LPA, P < 0.05),
albeit the absolute LPA levels were lower (Figure 4B).
Thus, our results demonstrated that secreted ATX from
Hep3B or Huh7 cells had lyso-PLD activity and TNF-α
induced ATX expression, secretion, and lyso-PLD activ-
ity, resulting increased extracellular LPA production from
LPC. Because Hep3B cells express higher level of both
ATX mRNA and ATX protein when compared with Huh
7 and HepG2, we mainly focused on Hep3B cell line for
more in-depth studies hereafter.
Secreted enzymatically active ATX promoted Hep3B 
cellinvasion
ATX has been shown to stimulate the migration and
invasion of a variety of cells types, including cancer cells,
fibroblasts, and vascular smooth muscle cells [7,21]. We
next determined whether ATX secreted by Hep3B cells
acted as a source of chemoattractant by utilizing inva-
sion/migration assays. As shown in Figure 5A, Hep3B
conditioned medium induced ~3-fold higher rate of
Hep3B cells invasion than EMEM/BSA did (P < 0.05),
suggesting an autocrine action. Specifically knockdown
of ATX in Hep3B cells resulted in significantly reduced
chemotactic potential of the conditioned medium from
Hep3B cells. To further elucidate whether ATX-LPA
linked to the invasion of Hep3B cells, we evaluated
Hep3B cell invasion in the presence and absence of exog-
enous LPC (18:1). We found that addition of LPC (1 μM)
to EMEM/BSA did not induce invasion of Hep3B cells.
Figure 2 Differential expression of ATX in human liver cancer cell 
lines (Huh7, Hep3B and HepG2), normal embryonic liver cell line 
CL-48, and normal primary hepatocytes. A. Comparison of ATX 
mRNA levels by qRT-PCR analysis. Columns are average ± SD from 
three independent experiments. B. Equal number of cells (4 × 105) 
were plated into 100 mm dishes and incubated in serum free EMEM 
containing 0.1% BSA for 24 hours. Cells were lysed with RIPA buffer and 
15 μg of lysates was used for SDS-PAGE and probed for ATX antibody, 
β-actin level was used as a loading control (top two pannels). 1/10 vol-
ume of concentrated medium was used for immunoblot (bottom pan-
el). An intense band of 110 kDa was detected in the cell lysate from 
Hep3B and Huh7 cells, which is corresponding to the positive ATX con-
trol. The sizes of the MW markers are shown on the right. rATX indicates 
recombinant ATX protein which is a positive control. IB indicates im-
munoblot.
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Page 6 of 14However, addition of LPC to Hep3B conditioned medium
resulted in a 1.8-fold greater rate of invasion above the
vehicle control (Figure 5A, b, P < 0.05). In addition, it was
noted that the presence of LPC in conditioned medium
from ATX siRNA-transfected Hep3B cells failed to
induce Hep3B cells invasion. These data suggest that LPC
itself is not a chemoattractant, and an ATX-dependent
action is required for the activity. To directly test whether
LPA is the molecule that involved in the invasion process,
we tested the effect of LPA on cell invasion in Hep3B
cells. LPA was found to dose-dependently induced the
invasion of Hep3B cells, which peaked at 5 μmol/L (Fig-
ure 5B). These data suggest that ATX-mediated conver-
sion of LPC to LPA is critical for cell invasion.
Figure 3 TNF-α induces ATX expression and secretion selectively in hepatoma cell lines Hep3B and Huh7. A. Effect of TNF-α on the expression 
of ATX. Serum starved cells were treated with or without TNF-α (10 ng/ml) for 16 hours. Results are the mean ± SD from three QRT-PCR experiments. 
**, P < 0.01. B. Starved Hep3B or Huh7 cells were treated with TNF-α (10 ng/ml) for 20 hours. Cell culture medium and cell lysates were collected. 15 
μg cell lysate were used for immunoblot analysis. IB indicates immunoblot.
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Figure 4 Up-regulation of ATX induced by TNF-α is associated with increased lysophospholipase D (lyso-PLD) activity by conversion of LPC 
into LPA in Hep3B and Huh7 cells. Serum starved Hep3B or Huh7 cells were treated with TNF-α (10 ng/ml) or vehicle (0.1%BSA/PBS) for 20 hours. 
A. Conditioned media (CM) or control media (DMEM or EMEM) were concentrated (40-fold) and assayed for ATX activity using the FS-3 compound. 
The results are shown as the average of relative fluorescence activity ± SD from three experiments. B. CM were incubated with 15 μM LPC (18:1) for 3 
hours at 37°C. Lipids were analyzed by liquid chromatography-mass spectrometry (LC-MS). Results are level of LPA (18:1) from three experiments and 
presented as mean ± SD. *, P < 0.05.
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Figure 5 Secreted enzymatically active ATX promoted Hep3B cell invasion. A. a, Hep3B cells were transfected with ATX siRNA or negative siRNA, 
and ATX expression was examined by immunoblot. b, serum starved Hep3B cells were chemoattracted by MEM/0.1% fatty acid-free BSA or condi-
tioned media (CM) plus or minus 1 μM LPC (18:1). Neg. CM, CM from Hep3B cells transfected with negative siRNA. 3B CM, CM from Hep3B cells; ATX 
siRNA CM, CM from Hep3B cells transfected with ATX siRNA. Each sample was tested in triplicate and results are reported as mean ± SD of invaded 
cells of two independent experiments, bars, SD. *, P < 0.05. c, representative fields of invaded and stained cells. B. a, starved Hep3B cells were chemoat-
tracted by various doses of LPA and representative fields of invaded cells are shown in b. **, P < 0.01.
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Page 8 of 14Nuclear factor-kappa B (NF-κB) mediated the basal and 
TNF-α induced ATX expression
Activation of TNF-α/NF-κB pathway has been shown to
contribute to inflammation-associated cancer such as
hepatitis-related HCC [22]. To determine whether NF-κB
is involved in the regulation of ATX expression, ATX pro-
moter region analyses were performed using
TFSEARCH: Searching Transcription Factor Binding
Sites (ver 1.3) http://www.cbrc.jp/research/db/
TFSEARCH.html and AliBaba 2.1 http://www.gene-regu-
lation.com/pub/programs/alibaba2/index.html. Further
analyses were performed using ConTra promoter align-
ment analysis tool (http://www.dmbr.ugent.be/prx/
bioit2-public/ConTra/index.php. Stringency: core = 0.95,
similarity matrix = 0.85). Two highly conservative con-
sensus sequences for NF-κB binding sites were identified
in ATX promoter region 2000 nt upstream of the tran-
scription start site from 9 eutherian mammals (Figure
6A) [23,24]. To evaluate the contribution of NF-κB to
basal transcription of ATX, the NF-κB activity was first
inhibited pharmacologically by a soluble inhibitor parthe-
nolide [25]. QRT-PCR results showed that parthenolide
(2.5 μM and 5 μM) treatment inhibited ATX expression
by 62% and 65% respectively (Figure 6B top panel). To
further confirm the role of NF-κB, we determined the
effect of NF-κB activity on expression of ATX using a sta-
ble cell line with reduced NF-κB activity. This cell line
over-expresses an inhibitor of kappaB alpha (IκBα)
mutant (S32A and S36A) (IκBαSR) and has been charac-
terized in our lab recently [26]. A significant reduction of
ATX expression compared to the vector control cell line
(Hep3B-pQCXIN) was observed in the mutant (S32A
and S36A) IκBαSR cell line (Figure 6C). Immunoblot
analyses confirmed that both parthenolide and overex-
pression of IκBαSR reduced ATX expression at the pro-
tein level. Since NF-κB is known as a main target
transcription factor of TNF signaling [27], we next deter-
mined whether NF-κB participates in the induction of
ATX by TNF-α. Hep3B cells were stimulated with TNF-α
in the presence or absence of parthenolide. Pretreatment
with parthenolide prevented the induction of ATX by
TNF-α at both mRNA and protein levels (Figure 7).
Expression of IκBαSR also blocked TNF-α induced ATX
expression in Hep3B-IκBαSR cells. Together, these data
indicate that NF-κB activity plays a key role in the regula-
tion of basal and TNF-α induced ATX expression.
Discussion
This is the first report to study the expression and the
functional roles of ATX in human HCC. We showed for
the first time that ATX protein was over-expressed in
human HCC tissues compared with that in normal con-
trols. Enhanced expression of ATX in HCC is signifi-
cantly correlated with liver inflammation, cirrhosis, as
well as risk factor such as hepatitis. ATX was also over-
expressed in human hepatoma cell lines Hep3B and Huh7
cells compared to hepatoblastoma HepG2 and normal
hepatocytes.
ATX-null mice embryos failed to develop into mature
vessels and died at E11.5 [9]. While ATX over-expression
was presented in various cancers and promotes tumor
progression by stimulating angiogenesis, tumor cell sur-
vival, growth, migration and invasion [6-8]. Recently,
Mills's lab demonstrated that expression of ATX or LPA
receptor in mammary epithelium of transgenic mice con-
tributes to the initiation and progression of estrogen
receptor (ER)-positive, invasive, and metastatic mam-
mary cancer [28]. Our observations showing the overex-
pression of ATX in HCC tissues and cell lines, as well as
its relative low levels in normal liver cell lines and tissues
imply its important role in both liver physiological and
pathological activities.
Being the key enzyme with lyso-PLD activity, the aber-
rant expression of ATX has the potential to alter the deli-
cate balance between LPA signaling and LPC signaling in
the local liver microenvironment. LPC is phospholipid
with both proinflammatory activity and immunoregula-
tory activity by stimulating the expression of a serial of
genes, including NO synthase, monocyte chemoattrac-
tant protein-1 (MCP-1), inter-cellular adhesion molecule
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1)
and growth factors in endothelial cells [29-33]. In addi-
tion, LPC has been reported to promote vascular smooth
muscle cell proliferation, attract monocytes, inhibit
endothelium dependent relaxation, reduce endothelial
cell migration, and promote the development of mature
dendritic cell [34-37]. Moreover, LPC is also required for
the cytotoxic response of human NK cells to tumor cells
[38]. On the other hand, LPA mediates a broad range of
biological activities such as wound healing, vascular
remodeling, and cell migration and survival. LPA and its
analogs were also proposed to be critical endogenous
mediators that regulate survival, motility, proliferation,
and differentiation of oval cell/hepatocyte progenitors in
liver regeneration [39]. Oval cell proliferation was pro-
posed to be associated with an increased risk for develop-
ment of HCC with advancing liver disease, particularly
when cirrhosis is present [40]. Serum ATX activity and
plasma LPA level were increased in chronic hepatitis C in
association with liver fibrosis [41]. Interestingly, we also
found that ATX over-expression in HCC was associated
with liver cirrhosis. The aberrant production of LPA may
bind to its receptors and results in the altered activation
of LPA signaling pathways, including, but no limited to
activation of the PI3K-AKT, Ras/MEKK/MAPK, p38
MAPK, and JNK pathways. These signaling pathways
have been shown to be actively involved in HCC develop-
ment by controlling angiogenesis, cell motility, cell prolif-
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Figure 6 NF-κB mediates the basal expression of ATX. A. Alignment of the ATX promoter region 2000 nt upstream of the transcription start site 
from 9 eutherian mammals. Two highly conservative consensus sequences for NF-κB binding sites are identified. B. Starved Hep3B cells were treated 
with parthenolide (0, 2.5 or 5 μM) for 16 hours. C. ATX expression in stable cell line Hep3B-IκBαSR which NF-κB activity was blocked by mutant IκBα 
(IκBαSR). Vector infected cell line Hep3B-pQCXIN served as control; IκBαSR indicates Hep3B-IκBαSR cells; pQCXIN indicates Hep3B-pQCXIN cells. ATX 
mRNA expression was determined by qRT-PCR (top panel in B, C), Values are the mean ± SD of three experiments. ** P < 0.01, * P < 0.05. ATX protein 
expression was determined by immunoblot (IB) (Bottom panel in B, C). β-actin expression was used as a loading control.
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Page 10 of 14eration and survival [42,43]. Therefore, the aberrant
expression of ATX along with the consequently abnormal
production of LPA in the liver microenvironment may
fuel the process of liver carcinogenesis.
Chronic inflammation has long been associated with
the development of liver cancer. Three lines of evidence
obtained from the current study support a link between
ATX expression/function to inflammation in liver dis-
eases. First, our immunohistochemistry data from human
liver tissue showed the differential expression of ATX in
HCC with different etiologies. Hepatitis literally means
inflammation of the liver, and is the major cause of HCC.
ATX expression in hepatitis-related HCC tissues is signif-
icantly elevated compared to those HCC tissues devel-
oped from non-cirrhotic "non-inflammatory"
background which indeed show no signs inflammatory
cell infiltration as we observed in the samples from
patients with chronic active hepatitis or steatohepatitis.
Secondly, the ATX expression levels correlated well to the
derivative origins in HCC cell lines related to inflamma-
tion. Hep3B cells were derived from a patient with hepati-
tis and therefore may have unique response systems that
are associated with the inflammatory background of a
hepatitis infected liver [44]. Rice lab showed that Huh7
cells had a favorable cellular environment for hepatitis C
virus replication [45]. We use it as a second cell line that
may respond to inflammatory mediators thereby calling
attention to unique signals associated with inflammatory
associated cancers. But we need to be cautious on this
data since Huh 7 cells are not well characterized although
they were derived from a Japanese patient with well dif-
ferentiated HCC [46]. In contrast, HepG2 is derived from
a human hepatoblastoma which almost always arise in an
otherwise normal liver and is most unlikely to be associ-
ated with inflammation [47,48]. Hep3B and Huh7 cells,
but neither HepG2 nor normal hepatocytes exhibit
enhanced expression of ATX. As we are focusing on the
mechanisms that potentially overlap between different
etiologies of inflammatory induced HCC, whether there
are any potential associations between viral antigens and
the ATX/LPA pathway remain to be further studied.
Finally, TNF-α, a pro-inflammatory cytokine, further
promoted ATX secretion and LPA production in Hep3B
and Huh7 cell lines. Moreover, the secreted enzymatically
active ATX promoted Hep3B cell migration/invasion,
which is dependent on extracellular LPC concentration
and can be directly demonstrated by LPA's effect. Our
mechanistic studies show that NF-κB activity is impor-
tant for TNF-α 's activity. Our previous work showed NF-
κB is constitutively activated in Hep3B, HepG2 and CL-
48 cell lines, but Hep3B has the strongest basal NF-κB
activity among these cell lines [26]. The differential
responsiveness of these cell lines to TNF-α in ATX stimu-
lation suggest that these cells may also have differential
signaling properties in responding to TNF-α, which
remains to be further investigated.
Conclusions
Taken together, we have shown for the first time the clini-
cal and biological significance of ATX in human HCC.
We have also demonstrated for the first time a novel reg-
ulation mechanism of ATX expression in human liver
cancer cells. The connection between TNF-α/NF-κB
pathway and ATX signaling provides new insight into the
molecular pathways involved in HCC pathogenesis and
indicates that ATX may play a potential role in the con-
nection between inflammation and tumorigenesis in the
complex liver microenvironment. Whether this influ-
Figure 7 NF-κB mediates TNF-α-induced expression of ATX. Par-
thenolide pretreated Hep3B cells (4 hours), and stable cell lines Hep3B-
IκBαSR and Hep3B-pQCXIN were stimulated with or without 10 ng/mL 
human TNF-α for 16 hours. ATX mRNA expression was determined by 
qRT-PCR (top panel), Values are the mean ± SD of three experiments. 
** P < 0.01, * P < 0.05. ATX protein expression was determined by im-
munoblot (IB) (Bottom panel). β-actin expression was used as a loading 
control.
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Page 11 of 14ences initiation, promotion, or metastatic potential
remains to be further studied. Since inflammation is the
most potent risk factor for human HCC, these findings
are highly significant for this research field.
Methods
Reagents
TNF-α, parthenolide and fatty acid-free BSA were pur-
chased from Sigma (St. Louis, MO). LPC (1-oleoyl) was
obtained from Avanti Polar Lipids, Inc. (Birmingham,
AL). ATX activity assay reagents were from Echelon Bio-
sciences, Inc. (Salt lake City, UT, USA). Purified recombi-
nant ATX protein and rabbit polyclonal antibody against
ATX and were generous gifts from Dr. Timothy Clair
(National Cancer Institute, Bethesda, MD); the polyclonal
antibody against ATX was prepared by immunization of
rabbits with the peptide ARVRDIEHLTSLDFFRK.
Human liver tissue and cell lines
This study was approved by Indiana University Institu-
tional Review Board. Liver tumor tissue was collected
from patients undergoing resections for HCC at Indiana
University Hospital. Normal tissue (n = 10) was obtained
from patients undergoing non-liver disease related sur-
geries. The fresh tissue was formalin fixed, and paraffin
embedded for immunohistochemistry. Thirty-eight HCC
cases were applied for this study. Eleven of them had
HCV infection, seven had HBV infection and ten had
non-alcohol steatohepatitis (NASH), as confirmed by
serological testing or PCR testing of benign or tumor
DNA. Another ten cases of HCC samples were observed
in non-cirrhotic liver and they developed in an otherwise
normal liver and without identified risk factors. No path-
ological evidence of inflammatory infiltrates within the
background liver was identified, and here they are named
as normal-HCC.
CL-48, HepG2 and Hep3B cell lines were obtained from
American Tissue Culture Collection and were cultured in
Eagle's Minimum Essential Medium (EMEM) with 10%
fetal bovine serum at 37°C, 5% CO2. Huh7 cell line was a
generous gift provided by Dr. Charles M. Rice's lab (Rock-
efeller University, New York, NY) and was cultured in
Dulbecco's Modified Eagle's Medium (DMEM) with 10%
fetal bovine serum at 37°C, 5% CO2. Human normal pri-
mary hepatocytes were purchased from Lonza (Lonza,
Walkersville, MD) and maintained in hepatocyte culture
medium (Lonza, Walkersville, MD). Cells were serum-
starved overnight and then treated with TNF-α (10 ng/
ml) or parthenolide in serum free media containing 0.1%
BSA. Total RNA was extracted or cell lysate was prepared
after stimulation for the indicated time.
siRNA transfection
Small interfering RNA (siRNA) duplexe targeting human
ATX and negative control siRNA were purchased from
Ambion (Austin, TX). Cells were cultured to 60-70% con-
fluency and then transfected with 10 nM of ATX siRNA
or 30 nM negative siRNA using Transfection siPORT™
NeoFX™ kit (Ambion) according to the manufacturer's
recommendations. Transfected cells were incubated at
37°C and 5% CO2 for 68-72 hours. Cells were harvested
for total RNA or protein preparation and conditioned
media were collected for invasion assay.
Conditioned media and cell extracts preparation 
andimmunoblot analysis
Conditioned media were prepared by incubating 70%
confluent cells in 100 mm dishes for 24 hours in serum-
free MEM or DMEM containing 0.1% fatty acid-free
BSA. Conditioned media were harvested, clarified by
centrifugation, and filtered through a 0.22 μm filter. The
conditioned media were concentrated by Amicon Ultra-
15 Centrifugal Filter Units before using for immunoblot.
At the same time, total cell extracts were prepared from
cell monolayer incubated in RIPA buffer (50 mM Tris-
HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA, 1 mM sodium
orthovanadate, 1% NonidetP40; 1% sodium deoxycholate;
0.1% sodium dodecylsulfate (SDS), 2 mM phenylmethyl-
sulfonylfluoride (PMSF) and protease inhibitor cocktail.
Fifteen micrograms of total cellular protein was resolved
by SDS-PAGE. Blots were probed with appropriate anti-
bodies. Anti-β-actin was used for loading control.
Quantitative real time RT-PCR (qRT-PCR)
Total RNA was isolated from cells using the RNeasy kit
following the manufacturer's instructions (Qiagen, Valen-
cia, CA). 2 μg total RNA was reverse-transcribed in a
total reaction volume of 20 μl using the high capacity
cDNA reverse transcriptase kit (Applied Biosystems, Fos-
ter City, CA) as described by the manufacturer. Single
stranded cDNA products were then analyzed by real-
time PCR using standard commercially available Taq-
MAN probes for ATX (Hs00196470_m1). The amount of
target gene was normalized to the internal standard 18S
rRNA (Hs99999901_s1) levels and reported as a relative
value.
ATX/lyso-PLD activity assay
The conditioned serum-free medium from Hep3B and
Huh7 cells with or without TNF-α stimulation was con-
centrated (40-fold) using Amicon Ultra 50,000 (Milli-
pore). EMEM and DMEM without cells were used as
control. ATX/lyso-PLD activity in concentrated condi-
tioned media was analyzed using fluorogenic substrate
FS-3 according to the manufacture protocol. Briefly, 10 ul
concentrated medium was mixed with 5 uM FS-3 and
assayed in 96-well plate. The change of fluorescent inten-
sity was measured by SpectraMax Gemini EM Fluores-
cence Microplate Reader (Molecular Devices, Sunnyvale,
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485 and 528 nm, respectively.
Lipid extraction and analyses
Lipids were extracted from conditioned media and ana-
lyzed using LC-MS (API-4000, Applied Biosystems)
[49,50]. Briefly, conditioned media were incubated with
15 μM LPC (18:1) for 3 hrs at 37°C. 1.3 mL samples were
mixed with 3 mL of MeOH/chloroform (2:1) following
the addition of 10 μL of 14:0 LPA (1 μM) as an internal
standard and 10 μL of HCl (6N). The samples were vor-
texed for 1 min and incubated on ice for 10 min. Chloro-
form (1 mL) and PBS (1 ×) (0.5 mL) was added to separate
the phases and samples were vortexed for 1 min prior to
centrifugation (1,750 g for 10 minutes, at 10°C). The
lower phase was transferred to a new glass tube. The
upper phase was re-extracted using 2 mL chloroform and
combined with the lower phase. After evaporating the
solvent under nitrogen at room temperature, the dried
lipids were re-suspended respectively in 100 μl of MeOH
and 10 μL of sample will be used for Mass spectrometry
(MS) analyses. Typical operating parameters for MS will
be as follows: nebulizing gas (NEB) 15, curtain gas (CUR)
8, collision-activated dissociation (CAD) gas 35, electro-
spray voltage 5000 with positive-ion MRM mode, and a
temperature of heater at 500°C. Precursor mode 153 will
be set as the daughter ions of LPA. In MRM mode, nega-
tive monitoring ions will be at m/z 435 (the parent ion)-
153 (the product ion) for 18:1 LPA. The dwell time in the
MRM mode will be 75 ms. A TARGA C18 5 μM, 2.1 mm
ID× 10 mm TR-0121-C185 (Higgins Analytical, South-
borough, MA USA) HPLC column was used for the sepa-
ration of different phospholipids and for the detection of
LPAs. The mobile phase A was MeOH/water/NH4OH
(90:10:0.1, v/v/v). The HPLC separations will be 12 min/
sample using the following scheme: 1) 100% A for 3 min
with a flow rate at 0.2 mL/min; 2) the mobile phase will
be changed from 100% A to 100% B in 2 min with a flow
rate from 0.2 to 0.8 mL/min; 3) a constant flow rate of 0.8
mL/min for 5 min; 4) the mobile phase will be changed
from 100% B to 100% A in 1 min with a flow rate from 0.8
to 0.2 mL/min; and 5) constant flow rate of 0.2 mL/min
for 1 min.
Cellular migration/invasion assays
According to previously described methods [26], invasion
assay was performed by using BD BioCoat™ Matrigel™ 24-
well invasion chamber (8 μM pore size). In brief, cells
were serum-starved overnight and re-suspended into
serum free MEM containing 0.1% fatty acid-free BSA. 5 ×
104 cells were added to the top insert, and 750 μl of condi-
tioned medium with or without 1 μM LPC (18:1) was
added to the bottom chamber. To determine the effect of
LPA on the invasion, serum-free MEM containing 0.1%
fatty acid-free BSA with or without LPA (0, 0.1, 1, 5 μM)
were added to the bottom chamber. After 24 hours incu-
bation at 37°C in a CO2 incubator, non-invaded cells were
removed from the upper surface of the filter with the cot-
ton swab; cells that migrated through the gel insert to the
lower surface of the membrane were fixed with 100%
methanol, stained with 1% Toluidine blue and counted
using a light microscope at 50 × magnification. Each sam-
ple was tested in triplicate at least in two independent
assays. Results were expressed as mean cell number per
field ± SD.
Immunohistochemistry
Serial 5-micron thick sections of formalin-fixed paraffin
embedded tissue were cleared with xylene and rehydrated
through graded ethanol and finally immersion in distilled
water. Slides were then rinsed in Tris-buffered saline
(TBS). Antigen retrieval was performed by using the
Dako Target Retrieval kit (Dako, Carpinteria, CA) con-
taining a citrate buffer (pH 6.0) for 10 min at 95°C. Dako's
Avidin Biotin blocking system was used for 10 min, and
the tissue sections were then rinsed with TBS. The non-
specific binding sites were blocked by incubating with
Dako's Protein Block for 10 min. Tissue sections were
then incubated with the polyclonal rabbit antibody
against ATX (7.8 μg/ml) overnight at 4°C. After washing
with TBS, the secondary antibody, Dako Link (Dako
LSAB2 kit) was applied for 20 min and then rinsed with
TBS. Additional washing was followed by incubation with
streptavidin horseradish peroxidase (Dako Label, LSAB2
kit) for 20 min. Immunoreactivity was visualized by incu-
bation of sections with 3, 3'-diaminobenzidine in the
presence of hydrogen peroxide. Sections were counter-
stained with light hematoxylin and mounted with a cov-
erslip. All of the procedures were performed at room
temperature except the primary antibody incubation.
Microscopic fields evaluated and scored were those with
the highest degree of immunoreactivity ("hot spots"). Five
fields (40 × fields) per section were analyzed. An intensity
score was assigned to each case on a scale from negative
to high (0: no staining; +1: weak staining; +2: moderate
staining; and +3: strong staining).
Statistical analysis
Data are presented as means ± SD. Analysis of the signifi-
cance of differences between two groups was performed
by two tailed student's t-test using Instat software
(GraphPad, San Diego, CA). P-values of < 0.05 were con-
sidered statistically significant. Fisher's exact test was
used for the ATX immunoreactivity analysis, and P value
< 0.05 was deemed significant.
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